Key result
Larger mammary adipocyte diameter is not linked to worse overall survival after BMI adjustment.
Why the study?
BMI has limitations in assessing adiposity and metabolic dysfunction, whereas mammary adipocyte hypertrophy may better reflect obesity's biological impact on breast cancer prognosis.
Is mammary adipocyte diameter associated with overall and recurrence-free survival in breast cancer patients, independently of BMI?
Cohort (n=2,211)
No
Is mammary adipocyte diameter associated with overall and recurrence-free survival in breast cancer patients, independently of BMI?
Larger mammary adipocyte diameter is associated with poorer overall survival in breast cancer patients, but this association is largely accounted for by BMI.
Answers are grounded in this paper and cite their sources.
Adipocyte diameter adds no independent prognostic value beyond BMI; leaves open whether it captures distinct biology in breast cancer cohorts.
e12720 Background: Obesity is associated with poorer breast cancer outcomes, yet body mass index (BMI) has limitations in assessing adiposity and metabolic dysfunction. Mammary adipocyte hypertrophy may better reflect the biological impact of obesity on tumor behavior and breast cancer prognosis. We examined if mammary adipocyte diameter is associated with overall and recurrence-free survival in breast cancer patients, independently of BMI. Methods: Women with newly diagnosed invasive, non-metastatic breast cancer were recruited at the Centre des Maladies du Sein (Quebec, Canada) between 2000-2012. Mean mammary adipocyte diameter (μm) was measured on hematoxylin- and eosin-stained tissue sections located ≥1 cm from the tumor using automated segmentation in ImageJ. Patients were followed through December 31, 2023. Hazard ratios (HR) and 95% confidence intervals (CI) from adjusted multivariate Cox models estimated associations of mean adipocyte diameter (per 10 μm) with overall survival (OS) and recurrence-free survival (RFS). Analyses were also stratified by combined estrogen receptor (ER) and progesterone receptor (PR) status, in line with previous findings in the literature. Results: Among 2,211 women (median follow-up: 13.2 years), mean adipocyte diameter was 75.0 μm (range: 46.3-116.4), and 804 deaths occurred (36.4%) and 1,069 recurrences (48.3%) were observed. In adjusted analyses, each 10 μm increase in adipocyte diameter was associated with poorer OS (HR = 1.08; 95% CI: 1.00-1.17; p = 0.047) particularly among patients whose tumors were ER+/ PR- (HR = 1.25; 95% CI: 1.01-1.55; p = 0.041). However, these associations were attenuated and no longer significant after adjusting for BMI (HR = 1.01; 95% CI: 0.93-1.10; p = 0.80 and HR = 1.10; 95% CI: 0.85-1.41; p = 0.47, respectively). No significant association with RFS was observed, regardless of BMI adjustment. Conclusions: Larger mammary adipocyte diameter was associated with poorer overall survival, specifically in patients with ER+/PR- tumors. While BMI accounted for much of this association, adipocyte size may be related to other clinical outcomes in the cancer care continuum, such as the long-term metabolic effects of cancer treatments. Further research is needed to explore these relationships and their potential value in improving survivorship and tailoring patient care in breast cancer.
No takes yet. Share an insight, caveat, or question.
Diorio et al. (2026) conducted a cohort in invasive, non-metastatic breast cancer (n=2,211). Mammary adipocyte diameter was evaluated on overall survival (OS) (HR 1.01, 95% CI 0.93-1.10, p=0.80). Larger mammary adipocyte diameter was initially associated with poorer overall survival, but this association was no longer significant after adjusting for BMI.
Synapse has enriched 10 related papers. Consider them for comparative context: